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Abstract
The safe, targeted and effective delivery of gene therapeutics remains a significant barrier to their
broad clinical application. Here we develop a magnetic nucleic acid delivery system composed of
iron oxide nanoparticles and cationic lipid-like materials termed lipidoids. Coated nanoparticles
are capable of delivering DNA and siRNA to cells in culture. The mean hydrodynamic size of
these nanoparticles was systematically varied and optimized for delivery. While nanoparticles of
different sizes showed similar siRNA delivery efficiency, nanoparticles of 50–100 nm displayed
optimal DNA delivery activity. The application of an external magnetic field significantly
enhanced the efficiency of nucleic acid delivery, with performance exceeding that of the
commercially available lipid-based reagent, Lipofectamine 2000. The iron oxide nanoparticle
delivery platform developed here offers the potential for magnetically guided targeting, as well as
an opportunity to combine gene therapy with MRI imaging and magnetic hyperthermia.
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Gene therapy has the potential to treat a broad range of human diseases1. However, the main
barrier to safe and effective gene therapy remains the challenge involved in delivering these
macromolecules2. Viral vectors have shown great efficacy of nucleic acid delivery both in
vitro and in vivo, but serious safety issues continue to be a significant concern; in contrast,
non-viral systems offer a number of potential advantages, including stability, low
immunogenicity and toxicity3. Among the myriad of synthetic gene carriers that have been
studied, iron oxide is an attractive material for drug delivery and theranostics for several
reasons. First, iron oxide is biocompatible and biodegradable. Studies have shown that iron
metabolism occurs in the human body through multiple pathways4, and dextran-coated iron
Correspondence to: Daniel G. Anderson.
NIH Public Access
Author Manuscript
Nano Lett. Author manuscript; available in PMC 2014 April 21.
Published in final edited form as:













oxide nanoparticles have been clinically tested and approved by the FDA5. Second, the
magnetic properties of iron oxide enable targeted delivery by application of an external
magnetic field6. Third, magnetic nanoparticles can be used for MRI imaging and
hyperthermia7.
Functionalization of the iron oxide nanoparticle surface represents one of the key aspects to
developing these materials as drug delivery vehicles8. Highly monodisperse iron oxide
nanoparticles can be produced in large quantities by thermal decomposition9, and the
surfaces of these nanoparticles are most commonly coated with a layer of oleic acid or oleic
amine, which can only be dispersed in a non-polar organic solvent. However, covalent
conjugation of ligands to the iron oxide surface can compromise biocompatibility and
degradability8. Silica-coated magnetic nanoparticles are water soluble and easy to
functionalize, but lack biodegradability10. While catechol is degradable and has strong
adhesion to the iron oxide nanoparticle surface, extra steps are required during modification
to protect the catechol groups from oxidation11. Other functional groups, such as amines12
and carboxylates13, also have affinities for the iron oxide surface. Because this binding is
non-covalent, polymers are often employed to achieve stronger adsorption14. To enhance
stability further, these coating molecules are frequently crosslinked15, which compromises
degradability.
An alternative approach for non-covalent binding to the iron oxide surface relies on
hydrophobic interaction16. In one method, nanoparticles and lipids are first co-precipitated
and then re-dispersed in water17. In another method, the particles and lipids are incorporated
together through an emulsion formed by an organic solvent and water, and the excess
coating material was removed by magnetic separation18. These procedures often produce
particle aggregates of heterogeneous size and lower the final yield. Furthermore, a poorly
assembled lipid coating on the nanoparticle surface can detach during purification and result
in the formation of unstable particle aggregates17.
To address these challenges, we developed a simple method to coat iron oxide nanoparticles
with lipids and lipid-like molecules, which produces stable nanoparticles with low
polydispersity. In this method (Figure 1a), monodisperse iron oxide nanoparticles were first
dispersed along with oleic acid and lipids in chloroform. Instead of completely drying the
particles or forming emulsions, the solvent N-methyl-2-pyrrolidone (NMP) was added to
induce adhesion between the lipids and the nanoparticle surface. Subsequently the
nanoparticle and lipid mixture were sonicated under nitrogen protection. After coating the
nanoparticles, chloroform was thoroughly evaporated away, which prevented phase
separation when particles were transferred to the aqueous phase. Finally, the excess lipids
were removed together with NMP by simply dialyzing the nanoparticles against water. Since
NMP is miscible with both chloroform and water, nanoparticles remain soluble and avoid
precipitation, which is undesirable due to the formation of irreversible aggregates held
together by strong Van der Waals attractions19. Adding NMP also promotes the adhesion of
the lipids to the hydrophobic nanoparticle surface in a mild manner20, so that lipids are able
to fully rearrange and assemble into a more complete layer on the nanoparticle surface21. As
further demonstrated in Figure 1a, siRNA and DNA were then loaded onto the nanoparticle
surface by electrostatic interaction with the cationic lipid coating. Once adsorbed, rather
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than remain exposed at the particle surface, the siRNA and DNA molecules likely further
interact with and rearrange within the lipid coating, which can consist of multiple layers. In
this manner, the nucleic acids may embed within the lipid surface coating and thus be
protected from enzymatic degradation.
16 nm nanoparticles were used in our experiment. An extended period of sonication was
applied to keep the nanoparticles dispersed. After 5 hours of sonication, nanoparticles
formed clusters after being transferred to water, as seen in Figure 1b. Continued sonication
for an additional 2–3 hours resulted in the formation of individual nanoparticles, as shown in
Figure 1c. A detailed transmission electron microscopy (TEM) image revealed a complete,
uniform coating on the nanoparticle surface as shown in Figure 1d.
Developed with the aid of combinatorial library synthesis and screening, lipid-like materials
termed lipidoids have been shown to deliver siRNA delivery both in vitro and in vivo22. 25
lipidoids shown in Figure S1 were synthesized and evaluated for their utility in coating iron
oxide nanoparticles. The efficiencies of these formulations in delivering DNA and siRNA,
respectively, to cultured HeLa cells are shown in Figure S2. Interestingly, the most effective
lipidoid-coated nanoparticles for DNA delivery were also generally those that worked best
for siRNA delivery. Lipidoids incorporating alkyl tails of 12 to 14 carbons in length (C12
and C14) demonstrated the best efficiencies, which is consistent with previous reports22.
Since compound C14-200 was among the top performers in our initial in vitro screen for
both siRNA and DNA delivery, it was selected for further study in this report. As previously
described22, additional formulation stability was conferred by initially dissolving the
C14-200 lipidoid in chloroform together with 1,2-distearoyl-sn-glycero-3-phosphocholine
(DSPC), cholesterol, and mPEG2000-DMG, and the ratio of these components was
optimized for these experiments.
In order to test whether excess free lipids were completely purified from the nanoparticle
solution, HPLC (high-performance liquid chromatography) analysis of lipid content in
solution was carried out before and after the nanoparticles were extracted by means of an
external magnetic field. As shown in Figure S3, most of the lipids were associated with the
nanoparticles and were able to be removed by magnetically separating the nanoparticles
from the solution. Measurements of siRNA concentration using the RNA binding dye
RiboGreen further confirmed that the nucleic acids were associated with the positively
charged nanoparticles. After magnetic extraction of the nanoparticles, little free siRNA
could be detected in solution, as seen in Figure S4.
Based on the measurements of lipid and iron content of the nanoparticles after dialysis using
HPLC and ICP-MS (inductively coupled plasma mass spectrometry), in a typical
formulation, one nanoparticle was coated with ~1000 lipidoid molecules. For the DNA
transfections, the lipid to DNA weight ratio was 1:1, with 1 DNA molecule binding to ~3
nanoparticles. For the siRNA transfections, the weight ratio of lipidoid to siRNA was 5:1,
and ~100 siRNA molecules were bound onto each nanoparticle.
Both the DNA and the siRNA delivery efficiencies were tested in vitro using HeLa cells.
DNA transfection efficiency was characterized by the percentage of GFP positive cells as
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measured by fluorescence-activated cell sorting (FACS) analysis, whereas siRNA
transfection efficiency was measured with a dual luciferase reporter assay used in our
previous studies22.The transfection efficiency data were plotted out together with the
particle size measured by dynamic light scattering, as shown in Figure 2. In Figure 2a, as the
sonication progresses, the mean hydrodynamic size of the coated nanoparticles continues to
decrease from a few hundred nanometers to ~40 nm. Regardless of size, the zeta potentials
for all nanoparticles were measured to be ~+20 mV in 25 mM sodium acetate buffer. Figure
2b–2c show the efficiencies of these nanoparticles for DNA and siRNA transfection,
respectively. The optimal nanoparticle size for DNA delivery was 50–100 nm, for which the
delivery efficiency was ~90%. For smaller-sized nanoparticles, the delivery efficiency
decreased dramatically; for instance, nanoparticles of 40 nm in diameter yielded a DNA
transfection efficiency of only ~ 34%. In marked contrast, siRNA transfection efficiency did
not show significant variation when particles of different sizes were used, and 40 nm
nanoparticles mediated highly efficient siRNA transfection corresponding to ~90%
knockdown.
TEM images of DNA-loaded nanoparticles suggested a possible explanation for these
observations based on the binding of DNA and siRNA molecules to the nanoparticle
surface. In Figure S5, a thick amorphous layer was observed on the surface of nanoparticle
clusters after mixing with DNA; however, no such structures were observed with small
individual nanoparticles. The entrapment of DNA and siRNA on the nanoparticle surface as
measured by a nucleic acid intercalating dye assay provided further insight22. As shown in
Figure S6, DNA entrapment is low (<50 %) for nanoparticles smaller than 50 nm, whereas
siRNA entrapment is high (~90%) and roughly uniform for all nanoparticles regardless of
size.
DNA molecules have a persistence length of ~50 nm calculated by the conventional polymer
random walk model23, and free DNA molecules usually adopt a much larger size in solution.
Only by interacting with certain proteins can DNA be bent into a size much smaller than its
persistent length24. For a single 16 nm iron oxide nanoparticle, the curvature may be too
high for a DNA chain to wrap tightly around it using only relatively weak electrostatic
interactions, which may explain why the transfection efficiency was low when the
nanoparticles were smaller than 50 nm. However, since the bending energy is inversely
proportional to the square of the bending circle radius25, bending of DNA around larger
nanoparticle clusters requires much lower energies. Correspondingly, nanoparticle clusters
larger than 50 nm showed much higher delivery efficiencies for DNA. On the other hand,
since siRNA is a small 6 nm rod-like molecule, binding to small individual nanoparticles
and large nanoparticle clusters might be equally efficient, which may account for the
observation that siRNA delivery efficiency was roughly equivalent using nanoparticles of
different sizes.
Application of a magnetic field directing nanoparticles towards the cell surface resulted in
the enhancement of transfection efficiency (Figure 3). The left panel in Figure 3 shows the
higher fluorescence intensity observed following transfection of GFP-encoding DNA in the
presence of the magnetic field. Flow cytometry measurements further confirmed this
observation, as shown in the right panel in Figure 3. We hypothesize that this result is due to
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an increase in the physical concentration of DNA at the cell surface26. The dose-response
profiles in Figure 4a demonstrated that the transfection efficiency remained high even at
very low doses of DNA and siRNA. For DNA, a transfection efficiency of ~70% was
achieved with 25 ng of DNA per well of a 96 well plate (0.05 nM). For siRNA, ~80%
knockdown was achieved using 3 ng of siRNA per well (1.5 nM). In multiple experiments,
using a magnet consistently increased the transfection efficiency at the lowest doses by a
factor of approximately four, and the performance significantly exceeded that of the
commercial transfection reagent Lipofectamine 2000. Additional experiments revealed that
the transfection was accelerated as a consequence of the magnetic field, as shown in Figure
4b. For DNA delivery, in the presence of the magnet, a transfection efficiency of 50% was
achieved within 4 hours of incubation at the 25 ng per well dose (0.05 nM), and quickly
approached saturation after 7 hours of incubation; for siRNA,~80% knockdown was
achieved within just 1 hour at the 25 ng per well dose (12.0 nM). In contrast, transfection in
the absence of the magnet appeared to be much slower, and interestingly, displayed a
different kinetic profile.
At a dose of 25 ng of DNA per well (0.05 nM), the viability exceeded 95%, as displayed in
Figure S7. This observation is consistent with the low toxicities reported for lipidoid
molecules and iron oxide nanoparticles18, 22.Similarly, Renilla luciferase levels as measured
by the Dual-Glo assay also indicated low cytotoxicity during siRNA transfection at the
conditions tested.
In conclusion, we have developed and characterized a simple and versatile nanoparticulate
DNA and siRNA delivery vehicle using lipidoids and iron oxide magnetic nanoparticles.
Nanoparticles were obtained without the need for complicated synthesis and purification
procedures. The method outlined here represents a broadly applicable approach for coating
the surface of iron oxide nanoparticles with various lipids and lipid-like molecules. The size
control attainable by this approach may make it useful for in vivo applications, as it has been
reported that nanoparticles 50–200 nm in size are optimal for tumor targeting due to the
enhanced permeability and retention (EPR) effect27. Furthermore, using the lipidoid-coated
nanoparticles, more DNA and siRNA can be loaded onto magnetic nanoparticles as
compared with direct conjugation methods28.
Future studies will address the efficacy of these nanoparticles in mediating gene delivery to
other cell types. mRNA levels can be measured to determine knockdown of other genes of
interest as well as to assess changes in cellular phenotype. In addition, the incorporation of
iron oxide nanoparticles imparts new functionalities to the delivery vehicle, specifically
magnetic targeting, magnetic hyperthermia therapy and MRI imaging. The new delivery
system may also be generalized to facilitate intracellular delivery of other negatively
charged or hydrophobic drugs.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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(a) schematic plot of the procedure of coating iron oxide nanoparticles; transmission electron microscopy (TEM) images of (b)
particle clusters; (c) individual particles; (d) coating on the nanoparticle surface.
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(a) Particle size measured by dynamic light scattering versus sonication time; (b) DNA delivery efficiency for nanoparticles of
different sizes, (25 ng of DNA per well of a 96 well plate); (c) siRNA delivery efficiency for nanoparticles of different sizes (25
ng of siRNA per well of a 96 well plate).
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Comparison of delivery efficiency with and without a magnet: (a) fluorescence microscopy images of cells after the transfection
of plasmid DNA encoding green fluorescent protein (GFP) with and without the magnetic field; (b) fluorescence-activated cell
sorting (FACS) analysis. Based on analysis of non-treated cells, cells to the right of the gate (blue line) were considered GFP-
positive, while cells to the left of the gate were fluorescing at levels indistinguishable from background.
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Comparison of the delivery efficiency with and without a magnetic field: (a) in vitro DNA delivery dose response, compared
with Lipofectamine2000 at 25 ng DNA per well (0.05 nM); (b) DNA delivery efficiency upon varying the incubation time; (c)
siRNA delivery dose response, relative toLipofectamine2000 at 25 ng siRNA per well (12.0 nM); (d) siRNA delivery efficiency
upon varying the incubation time.
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